Among these proton exchangers, a primary role is played by CA IX, an enzyme overexpressed in many types of cancers, including prostate cancer, with the potential to represent both a promising tumour biomarker and a specific target for future cancer therapies13,30–33,37–41,.44 This evidence concerns the gene CA9 and neoplasm.